TM & Partners has advised NextCell in connection with its rights issue

TM & Partners has advised NextCell Pharma AB (publ) in connection with its rights issue of units, consisting of shares and warrants, of approximately SEK 40 million. In the event of full utilization of all outstanding warrants, the company can receive additionally a maximum of approximately SEK 113 million.

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up. NextCell’s shares are admitted to trading on Nasdaq First North Growth Market.

Our team consisted of:
Johan Wigh (Partner)
Jacob Elovsson Hultin (Associate)
Philip Bihl (Associate)

For more information, please contact Johan Wigh:
E-mail: johan.wigh@tmpartners.se
Phone: +46 76 00 283 26